Humana Inc. (HUM) Stock Analysis
Is HUM a good investment?
Humana Inc. (HUM) has a Plutrex AI rating of 63.0/100 as of November 09, 2026, indicating a Hold consensus. The stock is not classified as halal-compliant. Key strength: Forward EPS growth of 91.86% next year (411% above peer average of 17.97%) and 5-year CAGR of 23.43% (42% above peer 16.46%) represent the strongest recovery growth profile in managed care; Q3 2026 earnings confirmed direction with raised 2026 profit outlook (headline: 'Humana Lifts Outlook as Quarterly Revenue Jumps'). Main concern: Valuation demands perfection: P/E 42.22x (135% premium to peer 17.95x) on 0.81% net margins with ROE of 6.67% (51% below peer 13.65%) — the entire thesis requires flawless execution of 91.86% EPS recovery; stock has risen 3.9% since prior Hold, further widening the gap above fair value range of $390-$429.
Investment Summary
Humana (HUM) at $433.74 is a managed care turnaround story with exceptional forward growth optionality but trading above what the fundamentals currently justify. Current profitability is acutely distressed: operating margin 0.25% (vs. industry 3.85%), net margin 0.81% (vs. industry 2.36%), ROE 6.67% (vs. industry 13.65%), and trailing EPS growth of -17.9% (vs. peers +51.5%). The stock carries a 135% PE premium to peers (42.22x vs. 17.95x industry) despite inferior current earnings — a structurally dangerous combination. The investment thesis rests entirely on 91.86% next-year EPS growth (vs. peer average 17.97%) representing mean-reversion from a trough earnings base. Q3 2026 results (headline: 'Humana Stock Rises After Narrower-Than-Expected Loss, Raised 2026 Profit Outlook') confirmed the recovery is on track with raised guidance, the most positive catalyst since the prior report. The analyst consensus target of $506.44 implies 16.8% upside from $433.74, but the stock has drifted 3.9% higher since my prior Hold at $417.56, widening the gap from my entry zone of $388-$405. Financial fortress ($25.1B cash, D/E 0.61) prevents distress. HOLD — do not chase above entry zone.
Key Strengths
- Forward EPS growth of 91.86% next year (411% above peer average of 17.97%) and 5-year CAGR of 23.43% (42% above peer 16.46%) represent the strongest recovery growth profile in managed care; Q3 2026 earnings confirmed direction with raised 2026 profit outlook (headline: 'Humana Lifts Outlook as Quarterly Revenue Jumps')
- Financial fortress: $25.1B cash position and D/E of 0.61 (16.6% below peer average 0.73) provide multi-year runway to absorb margin compression without forced balance sheet actions; analyst consensus target of $506.44 implies 16.8% upside
- Revenue growth of 26.1% (504% above peer average of 4.32%) confirms exceptional market share capture and scale-building, while Q3 results showing narrower-than-expected loss signals MLR trajectory is improving
Key Concerns
- Valuation demands perfection: P/E 42.22x (135% premium to peer 17.95x) on 0.81% net margins with ROE of 6.67% (51% below peer 13.65%) — the entire thesis requires flawless execution of 91.86% EPS recovery; stock has risen 3.9% since prior Hold, further widening the gap above fair value range of $390-$429
- Profitability crisis unresolved in reported numbers: operating margin 0.25% (vs. peer 3.85%), benefit cost pressures explicitly flagged in news ('Continued benefit cost pressures suggest margin recovery remains gradual and may weigh on profitability in coming quarters') mean the recovery timeline is extended, increasing execution risk on the valuation multiple compression thesis
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
HUM's fundamentals remain bifurcated. Profitability crisis persists: operating margin 0.25% (93.5% below peer 3.85%), net margin 0.81% (65.7% below peer 2.36%), ROE 6.67% (51.1% below peer 13.65%), FCF $747M modest against $25.1B cash base. P/E of 42.22x is 135% above peer average of 17.95x — paying twice the peer multiple for one-third the peer net margin. PEG of 1.80 vs. peer 1.58 (14.4% premium) confirms modestly expensive on growth-adjusted basis. However, forward EPS growth of 91.86% (411% above peer 17.97%) and 5-year EPS CAGR of 23.43% (42% above peer 16.46%) are genuinely exceptional and represent the mathematical justification for the premium. Revenue growth of 26.1% (504% above peer 4.32%) demonstrates scale momentum. Balance sheet strong: $25.1B cash, D/E 0.61 (below peer 0.73). Normalized EPS recovery math: if EPS recovers to ~$19.50 on 91.9% growth and trades at 20-22x (peer-consistent), intrinsic value = $390-$429. At $433.74, the stock is 1-11% above this fair value range — the upside is real but the entry is suboptimal.
News Sentiment
Humana delivered a dose of cautious optimism this week as the managed care giant reported its third-quarter 2026 results, sending shares higher despite continued losses in its core Medicare Advantage business. The headline told the story investors needed to hear: 'Humana Stock Rises After Narrower-Than-Expected Loss, Raised 2026 Profit Outlook.' That's right — Humana is still losing money, but it's losing less than Wall Street feared, and management felt confident enough to raise their profit forecast for the full year. The company also reported that quarterly revenue jumped, with Humana officially lifting its outlook in filings titled 'Humana Lifts Outlook as Quarterly Revenue Jumps.' On the Q3 earnings call — summarized in 'What Humana Said on Its Q3 Earnings Call' — executives walked investors through their path back to profitability, emphasizing that the worst of the benefit cost spiral may be behind them. Analysts revised their forecasts ahead of the report, with the most accurate forecasters signaling cautious optimism. The bigger picture: Humana is fighting through one of the toughest stretches in its history, squeezed by soaring medical costs eating into its Medicare Advantage margins. But with 95% of its members in 4-star rated plans securing quality bonus payments, and cash reserves of $25 billion, the company has the firepower to weather the storm. The question for investors is whether the recovery comes fast enough to justify paying 42 times earnings today.
Risk Assessment
PRIMARY RISK: Execution risk on 91.86% EPS recovery — if benefit cost pressures persist longer than expected (explicitly flagged in news analysis), the forward P/E does not compress and the 42.22x trailing P/E becomes unjustifiable, creating significant downside to $350-$370. SECONDARY RISK: Medicare Advantage structural headwinds — membership losses in 2027 (noted in prior analysis) could impair the top-line growth engine, breaking the revenue-to-earnings leverage thesis. VALUATION RISK: Stock at $433.74 is 1-11% above my $390-$429 fair value range; a miss on the EPS recovery could reset to $340-$360. MITIGATION: $25.1B cash position + D/E 0.61 prevents distress scenario; Q3 raised outlook provides near-term sentiment support; stop at $358 (17.5% below entry) limits catastrophic loss. POSITION SIZE: Reduced to 2.5% (from normal 3.5%) to reflect execution uncertainty.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is HUM a halal stock?
No, Humana Inc. (HUM) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for HUM?
Humana Inc. (HUM) has a Plutrex AI rating of 63.0/100 with a Hold consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is HUM a good investment?
According to Plutrex AI, HUM has a Hold rating (63.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in HUM?
US stocks like HUM can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in HUM?
Plutrex AI identifies the main risks for HUM by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.